Overview
Toxin-mediated infectious botulism (Orphanet code 230800) is a rare but potentially life-threatening condition caused by the colonization of the gastrointestinal tract by Clostridium botulinum or other botulinum toxin-producing Clostridium species, with subsequent in vivo production and absorption of botulinum neurotoxin. Unlike classical foodborne botulism, where preformed toxin is ingested in contaminated food, this form involves actual infection of the intestinal tract with toxin-producing organisms. It is sometimes referred to as adult intestinal toxemia botulism or adult intestinal colonization botulism, as it represents the adult equivalent of infant botulism. The botulinum neurotoxin blocks the release of acetylcholine at neuromuscular junctions, affecting the peripheral nervous system and leading to descending flaccid paralysis. Key clinical features include symmetric cranial nerve palsies (diplopia, blurred vision, ptosis, dysarthria, dysphagia), progressive descending skeletal muscle weakness, and autonomic dysfunction including constipation, urinary retention, and dry mouth. In severe cases, respiratory muscle paralysis can occur, requiring mechanical ventilation. The condition primarily affects individuals with altered gastrointestinal anatomy or flora, such as those with a history of gastrointestinal surgery, inflammatory bowel disease, or prolonged antibiotic use, which may predispose to intestinal colonization. Treatment involves supportive care, particularly respiratory support, and administration of botulism antitoxin to neutralize circulating toxin. Antibiotics may be used to eradicate the colonizing organism, though aminoglycosides are generally avoided as they may worsen neuromuscular blockade. Recovery can be prolonged, often taking weeks to months, as it depends on the regeneration of new nerve terminals. Early recognition and prompt treatment are critical for improving outcomes and reducing mortality.
Also known as:
Clinical phenotype terms— hover any for plain English:
Variable
Can begin at different ages, from infancy through adulthood
Treatments
No FDA-approved treatments are currently listed for Toxin-mediated infectious botulism.
View clinical trials →Clinical Trials
View all trials with filters →No actively recruiting trials found for Toxin-mediated infectious botulism at this time.
New trials open frequently. Follow this disease to get notified.
Specialists
View all specialists →No specialists are currently listed for Toxin-mediated infectious botulism.
Treatment Centers
8 centersBaylor College of Medicine Rare Disease Center ↗
Baylor College of Medicine
📍 Houston, TX
🏥 NORDStanford Medicine Rare Disease Center ↗
Stanford Medicine
📍 Stanford, CA
🔬 UDNNIH Clinical Center Undiagnosed Diseases Program ↗
National Institutes of Health
📍 Bethesda, MD
🔬 UDNUCLA UDN Clinical Site ↗
UCLA Health
📍 Los Angeles, CA
🔬 UDNBaylor College of Medicine UDN Clinical Site ↗
Baylor College of Medicine
📍 Houston, TX
🔬 UDNHarvard/MGH UDN Clinical Site ↗
Massachusetts General Hospital
📍 Boston, MA
🏥 NORDMayo Clinic Center for Individualized Medicine ↗
Mayo Clinic
📍 Rochester, MN
👤 Mayo Clinic Center for Individualized Medicine
🏥 NORDUCLA Rare Disease Day Program ↗
UCLA Health
📍 Los Angeles, CA
Travel Grants
No travel grants are currently matched to Toxin-mediated infectious botulism.
Community
No community posts yet. Be the first to share your experience with Toxin-mediated infectious botulism.
Start the conversation →Latest news about Toxin-mediated infectious botulism
No recent news articles for Toxin-mediated infectious botulism.
Follow this condition to be notified when news becomes available.
Caregiver Resources
NORD Caregiver Resources
Support, advocacy, and financial assistance for caregivers of rare disease patients.
Mental Health Support
Rare disease caregiving can be isolating. Connect with counseling and peer support.
Family & Caregiver Grants
Financial assistance programs specifically for caregivers of rare disease patients.
Social Security Disability
Learn how rare disease patients may qualify for SSDI/SSI benefits.
Common questions about Toxin-mediated infectious botulism
What is Toxin-mediated infectious botulism?
Toxin-mediated infectious botulism (Orphanet code 230800) is a rare but potentially life-threatening condition caused by the colonization of the gastrointestinal tract by Clostridium botulinum or other botulinum toxin-producing Clostridium species, with subsequent in vivo production and absorption of botulinum neurotoxin. Unlike classical foodborne botulism, where preformed toxin is ingested in contaminated food, this form involves actual infection of the intestinal tract with toxin-producing organisms. It is sometimes referred to as adult intestinal toxemia botulism or adult intestinal coloni